Venture capital portfolio crisis: Q3 VC investment losses of $0.33/share (vs. $0.03 gain prior year) with full-year loss guidance tripled to $0.50, representing a significant earnings drag and suggesting material write-downs in biotech holdings Pervasive revenue weakness with no recovery visibility: Organic revenue declined across both core segments (DSA -3.1%, Manufacturing -5.1%) as management…

Our analysis rates this filing BEARISH. The HIGH concern level (7.5/10) reflects multiple converging negative signals that indicate both cyclical and structural challenges. The venture capital investment losses represent an unexpected $0.36 per share negative swing year-over-year, suggesting…

Concern level: HIGH (7.5/10). Key factors: Venture capital investment losses exploded to $0.33 per share in Q3 2025 versus $0.03 gain in Q3 2024, with full-year guidance tripled from $0.17 to $0.50 loss - representing material portfolio deterioration; Broad-based revenue decline of 1.6% organically with DSA segment down 3.1% and Manufacturing down 5.1%, indicating systemic weakness in…

Notable risk changes: Venture capital investment losses exploded to $0.33 per share in Q3 (vs. $0.03 gain prior year) with full-year guidance tripled to $0.50 loss - representing a material earnings headwind and potential biotech portfolio valuation crisis; Broad-based revenue decline across DSA (-3.1% organic) and Manufacturing (-5.1% organic) segments with management emphasizing 'uncertainty' and 'cautious'…

The model predicts CRL will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.